Recruiting

Implanted Device

Sponsor:

Comphya Inc.

Code:

NCT06968494

Conditions

Erectile Dysfunction Following Radical Prostatectomy

Eligibility Criteria

Sex: Male

Age: 30 - 70+

Healthy Volunteers: Not accepted

Interventions

Activation of pro-erectile nerves within the pelvic plexus

Study Details

Brief summary:

The goal of this clinical trial is to assess if a new device is safe to use as a potential treatment for erectile dysfunction following radical prostatectomy.

The main questions it aims to answer are:

  • Is the device safe?
  • Does the device works well? Are the participants satisfied with the device?

Participants will be implanted with the device during the ongoing prostatectomy surgery and will be asked to complete the following tasks during 6 months follow-up:

  • Come to the hospital for follow-up visits,
  • Complete questionnaires,
  • Activate the device every day,
  • Measure erection hardness.

Researchers will compare an implanted group (participants having the device) with a control group (participants not having the device) to see if the device works well.

Conditions

Erectile Dysfunction Following Radical Prostatectomy

Study ID

NCT06968494

Start date

Jun 5, 2025

Status verified date

Nov, 2025

Completion date

Apr, 2027

Anticipated

Primary completion date

Apr, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Male

Age: 30 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Men of ages between 30-75 years with indication for nerve-sparing prostatectomy surgery;
  • Cancer stage T1c and T2a;
  • Grade Groups 1 and 2 as well as low volume Grade Group 3 (Gleason score 4 + 3 = 7), as determined by biopsy (2 cores or less GG3) or single index MRI lesion of GG3 disease;
  • IIEF-15 erectile function domain score equal to or greater than 26;
  • Men interested in minimizing the effect of radical prostatectomy on erectile function;
  • Ability to read and understand patient information materials and willingness to sign a written informed consent.

Exclusion Criteria:

  • Men with neurological disease, including a history of spinal cord injury or trauma;
  • IIEF-15 erectile function domain score less than 26;
  • Failure to demonstrate adequate nocturne erectile function prioi prostatectomy (nocturnal RigiScan measure);
  • Men with PSA > 20 ng/mL;
  • History of ED, priapism and Peyronie disease;
  • History of previous pelvic surgery, trauma or irradiation therapy;
  • Currently have an active implantable device.
  • Patient diagnosed with neurologic degenerative diseases that may negatively impact erectile functions;
  • Identification of technical or clinical limitation to properly apply the use of nerve-sparing techniques during operation;
  • Inability to understand and demonstrate device use instructions;
  • Patients with insulin-dependent diabetes who suffer peripheral neuropathy or other diabetes associated complications;
  • Patient unwillingness to engage in sexual activity;
  • Patient is currently participating in another clinical investigation that would serve as a contraindication to implant a neurostimulator device to augment erectile function;
  • Have participated in any drug or device trial in the last 4 weeks or plan to participate in any other drug or device study during the next 24 months;
  • Possess any other characteristics that, per the investigator's judgment, may increase the risk or impair data collection for the procedure/study;
  • Patient is a member of a vulnerable population (Vulnerable participants include those who lack consent capacity, including the mentally ill, prisoners, cognitively impaired participants, and employee volunteers).

Study Design

Enrollment

20 participants

Anticipated

Allocation

Non randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Implanted group

Participants in the implanted group will be implanted with the study device during ongoing prostatectomy surgery.

no intervention: Control group

Participants in the control group will undergo standard prostatectomy and will not be implanted with the study device.

Interventions

Activation of pro-erectile nerves within the pelvic plexus

The study device is an active implantable device. The device activates the pro-erectile nerves by delivering electrical pulses. The daily delivery of electrical pulses to the pro-erectile nerves may allow participants to recover natural erectile function.

Primary outcome measure

  • Occurrence of adverse events [ Time Frame: 6 months ]
  • Occurrence of surgical complications [ Time Frame: 6 months ]
  • Occurrence of device deficiencies [ Time Frame: 6 months ]
  • Pain assessment [ Time Frame: 6 months ]

Central Contacts and Locations

Central contacts

Rana Harb

410-502-5500rharb1@jhmi.edu

Locations

Johns Hopkins Hospital

Recruiting

Baltimore, Maryland, United States, 21287

Contacts

Rana Harb

410-502-5500rharb1@jhmi.edu

Principal Investigator:

Christian Pavlovich, MD

More Information

Sponsor

Comphya Inc.

Last update posted

Nov 10, 2025

Last verified

Nov, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Comphya Inc. on 2025-11-10.